A recent study involving researchers with the Center for Clinical and Cognitive Neuropharmacology (CCCN), a Consortium member center, found that 60% of registered medical cannabis users in Minnesota had indications of "intractable pain," but that older and younger adults received significant differences in dosage. The study, led by Angela Birnbaum, PhD, and published in the journal Current Therapeutic Research, aimed to fill knowledge gaps around the distribution of cannabis products, their cannabidiol (CBD) and tetrahydrocannabinol (THC) content, and dosing among patients with qualifying conditions. The study also found that most products received by patients included THC-containing formulations, even for conditions where CBD is indicated. The authors say the complicated pharmacokinetics of CBD and THC, possible age-related changes in physiology, unknown efficacy, and the potential drug interactions—particularly in older patients—highlight the need for increased monitoring of patients who receive these products. Read more on the UMN Twin Cities website.